Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) has obtained approval for a change in the marketing licence holder of its Eszolam tablets from China's National Medical Products Administration, a Monday filing with the Hong Kong bourse said.
The company had, in November 2022, entered into an agreement with Guangxi Dahai Sunshine Pharmaceutical, which agreed to transfer its Marketing Authorization Holder (MAH) status to the former for Eszolam.
The drug is mainly used for anti-anxiety, insomnia or tension, fear, antiepileptics, and anti-convulsions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.